LP
ECYT

LMR Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

LMR Partners’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-130,633
Closed -$196K – 650
2017
Q2 		$196K Buy
+130,633
New +$281K 0.01% 527
2014
Q2 		– Sell
-22,450
Closed -$535K – 613
2014
Q1 		$535K Buy
+22,450
New +$326K 0.07% 125

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's ECYT Position: Q3 2017 in Review

LMR Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 130,633 shares — an estimated $196K sold.

LMR Partners first reported a position in ECYT in Q1 2014 and held it in 2 quarters. The position peaked at $535K in Q1 2014. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

  • LMR Partners reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 130,633 Endocyte, Inc. Common Stock shares in Q3 2017, an estimated $196K.
  • LMR Partners first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • LMR Partners's Endocyte, Inc. Common Stock position peaked at $535K in Q1 2014.
  • 63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.